Literature DB >> 7690105

[Palliative therapy of primary liver tumors].

C Kelm1, K Henneking, T Zimmermann, M Vollerthun, W Padberg.   

Abstract

In Europe and North America, primary liver tumors are rare. Resection is the only means of cure, but is possible in only 20-30% of the patients affected, so that in all other patients, i.e. the vast majority, only palliative treatment is possible. In a retrospective analysis we investigated the 68 patients we had treated for hepatocellular or cholangiocellular carcinoma of the liver. In 14 patients resection was possible, while 28 patients were treated by chemoembolization and 26 by intraarterial regional chemotherapy to the liver. There was no difference in tumor stage between the two groups receiving different palliative treatments. The patients in whom resection was performed, in contrast, mostly had less advanced tumors. For chemoembolization we used a mixture of Ethibloc, mitomycin, Adriamycin and cisplatin. Up to 1986, the intraarterial chemotherapy was performed with mitomycin and 5-FU. Since 1986 we have used Adriamycin and cisplatin. The overall median survival time was 8 months: after resection 17 months, after chemoembolization 6.5 months, and after intraarterial chemotherapy 6.5 months. There was a significant difference in survival between patients with tumor stage II and those with tumor stages III and IV. On comparing the survival time achieved with our treatments and that ensuing in the natural course of patients with liver tumor we found no improvement.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7690105     DOI: 10.1007/bf00184360

Source DB:  PubMed          Journal:  Langenbecks Arch Chir        ISSN: 0023-8236


  21 in total

1.  Role of surgery in the treatment of primary carcinoma of the liver: a 31-year experience.

Authors:  T Y Lin; C S Lee; K M Chen; C C Chen
Journal:  Br J Surg       Date:  1987-09       Impact factor: 6.939

2.  Prognosis of unresectable hepatocellular carcinoma: an evaluation based on multivariate analysis of 90 cases.

Authors:  Y Akashi; C Koreeda; S Enomoto; S Uchiyama; T Mizuno; Y Shiozaki; Y Sameshima; K Inoue
Journal:  Hepatology       Date:  1991-08       Impact factor: 17.425

3.  Transcatheter arterial embolization in unresectable hepatocellular carcinoma.

Authors:  R Yamada; K Kishi; T Sonomura; M Tsuda; S Nomura; M Satoh
Journal:  Cardiovasc Intervent Radiol       Date:  1990 Jun-Jul       Impact factor: 2.740

4.  Vascular patterns of liver tumors and their consequences for different therapeutic approaches.

Authors:  N B Ackerman; W B Hodgson
Journal:  Recent Results Cancer Res       Date:  1986

Review 5.  [Regional chemotherapy of liver tumors--analysis of status].

Authors:  P Schlag; P Hohenberger
Journal:  Chirurg       Date:  1988-04       Impact factor: 0.955

Review 6.  Review: the treatment of hepatocellular carcinoma.

Authors:  A A Dunk; H C Thomas
Journal:  Aliment Pharmacol Ther       Date:  1988-06       Impact factor: 8.171

7.  Chemoembolization for hepatocellular carcinoma.

Authors:  A P Venook; R J Stagg; B J Lewis; J L Chase; E J Ring; T P Maroney; D C Hohn
Journal:  J Clin Oncol       Date:  1990-06       Impact factor: 44.544

8.  [Capillary embolization. Part II. Occlusion of the entire arterial system of experimentally induced renal tumors ].

Authors:  G Richter; R Rohrbach; G W Kauffmann; J Rassweiler
Journal:  Rofo       Date:  1981-07

9.  [Chemoembolization of primary liver cancer].

Authors:  J Kollath; M Lorenz; C Hottenrott; D Liermann
Journal:  Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir       Date:  1990

Review 10.  [Therapy concepts in colorectal liver metastases. What is proven, what is open to discussion?].

Authors:  K H Muhrer; K Schwemmle
Journal:  Leber Magen Darm       Date:  1988-12
View more
  1 in total

Review 1.  Therapeutic modalities and prognostic factors for primary and secondary liver tumors.

Authors:  T Lehnert; G Otto; C Herfarth
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.